title: A phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis.
authors.affiliation: Department of Molecular Pharmacology, Stanford University School of Medicine, CA 94305-5332, USA.
authors.forename: J A
authors.initials: JA
authors.lastname: Wagner
authors.forename: M L
authors.initials: ML
authors.lastname: Moran
authors.forename: A H
authors.initials: AH
authors.lastname: Messner
authors.forename: R
authors.initials: R
authors.lastname: Daifuku
authors.forename: C K
authors.initials: CK
authors.lastname: Conrad
authors.forename: T
authors.initials: T
authors.lastname: Reynolds
authors.forename: W B
authors.initials: WB
authors.lastname: Guggino
authors.forename: R B
authors.initials: RB
authors.lastname: Moss
authors.forename: B J
authors.initials: BJ
authors.lastname: Carter
authors.forename: J J
authors.initials: JJ
authors.lastname: Wine
authors.forename: T R
authors.initials: TR
authors.lastname: Flotte
authors.forename: P
authors.initials: P
authors.lastname: Gardner
mesh_terms: D000293:Adolescent; D000328:Adult; D002908:Chronic Disease; D002985:Clinical Protocols; D003550:Cystic Fibrosis / Q000150:complications / Q000628:therapy*; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics* / Q000627:therapeutic use*; D000229:Dependovirus / Q000235:genetics; D005260:Female; D015316:Genetic Therapy; D005822:Genetic Vectors; D006801:Humans; D008297:Male; D008875:Middle Aged; D012852:Sinusitis / Q000150:complications / Q000628:therapy*
chemical_list: C505032:CFTR protein, human; D019005:Cystic Fibrosis Transmembrane Conductance Regulator